Trial reportGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2012
Memantine for axonal loss of optic neuritis.
Trial report in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 34 citations in OpenAlex.
- Effect of phenytoin on retinal ganglion cells in acute isolated optic neuritis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020Trial
- Neuroprotective Effects of Novel Treatments on Acute Optic Neuritis-A Meta-Analysis.Biomedicines · 2022Article
- Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis.JAMA neurology · 2020Article
- Improving Outcomes in Pediatric Multiple Sclerosis: Current and Emerging Treatments.Paediatric drugs · 2019Review
- The International Multiple Sclerosis Visual System Consortium: Advancing Visual System Research in Multiple Sclerosis.Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2018Review
- Using the Anterior Visual System to Assess Neuroprotection and Remyelination in Multiple Sclerosis Trials.Current neurology and neuroscience reports · 2018Review
- [Immunomodulation and neuroprotection in optic neuritis].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2016Review
- Re-evaluating the treatment of acute optic neuritis.Journal of neurology, neurosurgery, and psychiatry · 2015Review
- Vision and vision-related outcome measures in multiple sclerosis.Brain : a journal of neurology · 2015Review
- Inhibition of NR2B-Containing N-methyl-D-Aspartate Receptors (NMDARs) in Experimental Autoimmune Encephalomyelitis, a Model of Multiple Sclerosis.Iranian journal of pharmaceutical research : IJPR · 2014Article
- [Neuroprotective approaches].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2013Review
- Current options for the treatment of optic neuritis.Clinical ophthalmology (Auckland, N.Z.) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo determine the effect of memantine on axonal loss and visual function during the course of optic neuritis (ON).
methodsSixty ON patients in a single-center, institutional setting were randomly assigned to the memantine or placebo groups. Patients with first attack of acute unilateral optic neuritis, with visual symptoms of 8 days' duration or less were enrolled in this trial. No patient had known multiple sclerosis, and none had taken immunomodulatory agent prior to or at the time of presentation. For all patients, the following characteristics were recorded and compared at initial presentation and 3 months afterward: visual acuity, retinal nerve fiber layer (RNFL) thickness, visual field parameters (mean deviation and pattern standard deviation), visual evoked potential, and contrast sensitivity.
resultsFifty-four patients completed the 3-month follow up. There were no significant differences between the placebo and memantine groups for any of the characteristics at initial presentation. After 3 months, the only statistically significant difference between the two groups was in RNFL thickness. Memantine group subjects had higher thickness in nasal (P = 0.01), superior (P = 0.006), inferior (P = 0.01) quadrants and average (P = 0.01). However, temporal quadrant thickness was not different between two groups (P = 0.35).
conclusionMemantine was effective in reduction of RNFL thinning, although this structural difference was not associated with improved visual function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.